Levi & Korsinsky announces that a class action lawsuit has been
commenced in the United States District Court for the District of
Massachusetts on behalf of investors who purchased Vertex
Pharmaceuticals Incorporated ("Vertex" or the "Company") (NasdaqGS:VRTX)
securities between May 7, 2012 and May 29, 2012.
For more information, click here: http://zlk.9nl.com/vertex-pharmaceuticals.
The complaint alleges that during the Class Period the Company made
false and/or misleaing statements regarding the positive nature of
interim data from its Phase 2 study of the drugs VX-809 and Kalydeco.
On May 29, 2012, Vertex issued a series of press releases in which it
acknowledged that the results from its clinical trials were not as
positive as previously indicated. These results were further restated on
June 28, 2012.
If you suffered a loss in Vertex you have until July 28, 2014 to request
that the Court appoint you as lead plaintiff. Your ability to share in
any recovery doesn't require that you serve as a lead plaintiff. To
obtain additional information, contact Joseph E. Levi, Esq. either via
email at firstname.lastname@example.org or by
telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/vertex-pharmaceuticals.
Levi & Korsinsky is a national firm with offices in New York, New
Jersey, Connecticut, and Washington D.C. The firm's 26 attorneys have
extensive expertise in prosecuting securities litigation involving
financial fraud, representing investors throughout the nation in
securities and shareholder lawsuits. Attorney advertising. Prior results
do not guarantee similar outcomes.
[ Back To NFVZone's Homepage ]